Thursday 8 October 2026
Morning EditionRSS
ZOTPAPER

News without the noise

ZOTPAPER
Startups

Healthleap raises $38M for AI platform that flags hospital patients at risk of undiagnosed conditions

Seed and Series A rounds backed by Sequoia, First Round Capital and Hummingbird Ventures

By LineZotpaper
Published
Read Time2 min
Sources3 outlets
Healthleap, a startup using language models to scan patient records and flag individuals at risk of undiagnosed conditions such as malnutrition and delirium, has raised $38 million in seed and Series A funding. The company, founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, has grown from three hospital partners to more than 50 over the past year and now counts Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare among its customers.

The financing consists of an $8 million seed round co-led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures. The company is not disclosing its valuation.

Healthleap originally built a clinical nutrition tool for dietitians but later pivoted to a general-purpose platform that analyses electronic health records. Each night, the system reviews every adult inpatient's lab results, vital signs, weights, medications, diet orders, diagnoses and clinicians' written notes. The next morning, it writes a risk score into the care team's existing workflow via a dashboard.

“A patient's chart holds two kinds of data. Labs, weights, and vital signs sit in structured fields, but the most telling signs sit in clinicians' written notes: poor appetite, recent weight loss, muscle loss, trouble swallowing,” CEO and co-founder Josiah Meyer told TechCrunch. “Our developing approach is extracting affirmative or negated mentions of these clinical concepts in an easily extensible and scalable way.”

The software does not diagnose patients; it only highlights items that need additional review. Besides malnutrition and delirium, Healthleap has built programs to identify aspiration pneumonia, pressure ulcers and risk of readmission for congestive heart failure, which are undergoing further clinical validation.

Research cited by the company indicates that 20% to 50% of hospital inpatients are malnourished, and malnutrition has been linked to longer stays, impaired wound healing and higher morbidity and mortality. Revenue has grown more than 10-fold over the past year, Josiah said.

§

Analysis

Why This Matters

  • Undiagnosed conditions such as malnutrition and delirium affect a large proportion of hospital patients and can lead to worse outcomes and higher costs.
  • AI tools that surface at-risk patients early promise to improve care and reduce strain on healthcare systems.
  • The rapid adoption by major US hospitals signals growing appetite for clinical AI, though validation and integration challenges remain.

Background

Healthleap was founded in South Africa in 2022 as a nutrition-focused tool for dietitians before pivoting to a broader hospital screening platform. Malnutrition is a well-documented problem: studies suggest 20% to 50% of inpatients are malnourished, yet the condition frequently goes undiagnosed in busy hospital settings. The company's approach uses language models to parse unstructured clinical notes alongside structured data, a technique that is becoming more common in healthcare AI.

Key Perspectives

Hospitals and care teams: They gain a tool that systematically screens every adult inpatient overnight, potentially catching issues that manual review might miss, and integrates into existing workflows with a risk score dashboard. Clinicians: Some may welcome the assistance with workload, but others may be concerned about false positives or the system overriding clinical judgment. The company emphasises that the software flags items for review, not diagnoses. Critics and skeptics: Questions remain about data privacy, algorithmic bias across different patient populations, and the need for rigorous clinical validation beyond the conditions already in use. The startup's programs for pneumonia and pressure ulcers are still being validated.

What to Watch

  • Expansion into additional conditions and further clinical validation results, especially for aspiration pneumonia and congestive heart failure readmission.
  • The pace of hospital adoption: whether Healthleap can sustain its recent growth trajectory and add large health systems.
  • Potential regulatory scrutiny as AI-based clinical decision support tools become more widespread.

Sources

Zotpaper

Written by software from the reporting listed above, scored by an automated standards desk, and published without a person reading it first. If something here is wrong, tell the editor and it will be put right.

How we workReport an errorSubscribe